Details:

Alternative Title:
Emerg Infect Dis
Personal Author:
Tan, Emily L.C. ; Ooi, Eng Eong ; Lin, Chin-Yo ; Tan, Hwee Cheng ; Ling, Ai Ee ; ... More +
Tan, Emily L.C. ; Ooi, Eng Eong ; Lin, Chin-Yo ; Tan, Hwee Cheng ; Ling, Ai Ee ; Lim, Bing ; Stanton, Lawrence W. Less -
Description:
Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, b-1b, a-n1, a-n3, and human leukocyte interferon a. These findings support clinical testing of approved interferons for the treatment of SARS.
Subjects:
[+]
Agents Antiviral Antiviral Agents Antiviral Drugs Antivirals Coronavirus Infection Dose-Response Relationship, Drug Humans In Vitro Research SARS Virus Severe Acute Respiratory Syndrome
Source:
Emerg Infect Dis. 10(4):581-586.
Document Type:
Journal Article
Collection(s):
Emerging Infectious Diseases
Main Document Checksum:
[+]
urn:sha256:a3b49ce2f9c4a9040050342faec537ec7cdd8ecc420c8504c8cc47e5729c324e
Download URL:
https://stacks.cdc.gov/view/cdc/14395/cdc_14395_DS1.pdf
File Type:

Supporting Files

• 	03-0458-F1.gif	gif
  	03-0458-F1.jpg	jpeg
  	03-0458-F2.gif	gif
  	03-0458-F2.jpg	jpeg
  	03-0458.nxml	txt
  	license.txt	txt

More +